NEW YORK Health insurer Cigna will stop covering GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, in its employee health plan effective July 1, according to materials viewed by Reuters
La Vignera S, Condorelli RA, Calogero AE, Cannarella R, Aversa A
However, certain digestive and monitoring considerations may become more important during treatment
If you experience persistent headaches, fatigue, mood changes, and other symptoms that dont resolve within a few days, contact your prescribing clinician immediately to assess your condition and prevent possible complications
Some patients find it helpful to track meals or keep a food diary to ensure they are getting enough nutrients while adjusting to the medication